GlassScriptPhysician profile
Richard Dean Jantz
NPI 1508853243
$8,243.62
in general payments reported to CMS, 2019-2025
41 companies · $49.46 in 2025
The $49.46 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044 · 2020: $919 · 2021: $1,263 · 2022: $1,741 · 2023: $1,882 · 2024: $345 · 2025: $49.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $862.68 | 2021-2023 | Optimizer |
| Boston Scientific Corporation | $753.32 | 2019-2025 | Watchman Access System, Watchman |
| Pfizer INC. | $575.31 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $573.71 | 2019-2024 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $521.45 | 2019-2023 | |
| Cvrx, INC. | $506.98 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.56 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $328.69 | 2020-2023 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $327.34 | 2019-2023 | Opsumit, Uptravi |
| Abiomed | $297.79 | 2019 | |
| Amgen INC. | $282.05 | 2019-2023 | Repatha |
| Akcea Therapeutics, INC. | $270.15 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.70 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $253.11 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $239.98 | 2021-2023 | Verquvo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Jantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.